Lutikizumab

Lutikizumab (ABT-981) is an anti-IL-1α and IL-1β dual variable domain immunoglobulin. Lutikizumab binds and inhibits IL-1α and IL-1β. Lutikizumab can be used for the research of osteoarthritis[1].

Product Specifications

CAS Number

[1791411-57-8]

Product Name Alternative

ABT-981

UNSPSC

12352203

Target

Interleukin Related

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/lutikizumab.html

Purity

96.54

Solubility

10 mM in DMSO

Smiles

[Lutikizumab]

Molecular Weight

(196.57 kDa)

References & Citations

[1]Lacy SE, et al. Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig (TM) ) molecule that specifically and potently neutralizes both IL-1α and IL-1β. MAbs. 2015;7 (3) :605-19.